Active Ingredient(s): Talazoparib Tosylate
FDA Approved: * October 16, 2018
Pharm Company: * PFIZER INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Talzenna Overview

Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.[2] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[3][4] It was approved in October 2018, in the United States and June 2019, in the European Union for germline BRCA-mutated, HER2-negative locally advanced or metasta...

Read more Talzenna Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Talazoparib

Recent Talzenna Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Talazoparib Tosylate
  • Capsule: 0.25mg, 1mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Talzenna: (3 results)

Sorted by National Drug Code
  • 0069-0296 Talzenna .25 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
  • 0069-1195 Talzenna 1 mg Oral Capsule by Pfizer Laboratories Div Pfizer Inc
  • 63539-295 Talzenna 1 mg Oral Capsule by U.S. Pharmaceuticals

Other drugs which contain Talazoparib Tosylate or a similar ingredient: (1 result)